Search

Your search keyword '"Nakamura, Ryotaro"' showing total 257 results

Search Constraints

Start Over You searched for: Author "Nakamura, Ryotaro" Remove constraint Author: "Nakamura, Ryotaro" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years Language english Remove constraint Language: english
257 results on '"Nakamura, Ryotaro"'

Search Results

4. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

5. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

6. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

7. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

8. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

9. A Day 14 Endpoint for Acute GVHD Clinical Trials

10. Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma

12. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

13. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

14. Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation

15. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

16. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

19. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab

20. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

21. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

22. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines

23. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

24. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

26. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

29. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

32. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

34. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.

35. Neuronal and non-neuronal functions of the synaptic cell adhesion molecule neurexin in Nematostella vectensis.

36. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

37. High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.

38. Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation.

39. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide

41. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

42. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis

43. Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians.

44. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.

45. Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients.

46. Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study

50. Lack of RBC transfusion independence by Day 30 following allogeneic hematopoietic stem cell transplant strongly predicts inferior survival and high non‐relapse mortality in acute myeloid leukemia patients.

Catalog

Books, media, physical & digital resources